Karen Nishida, MD
Gynecologic Oncology · Stamford, CTNPI 1962509653
Payments from drug & device makers
What this record shows
This record is dominated by education: $16,000 of the $26,441 with a category attached, or 60.5%. Intuitive Surgical accounts for 65.1% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $18,129 and has fallen 97.3% since, to $487 in 2025. Among gynecologic oncology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $307.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$17K
- Tesaro, Inc.$5K
- GSK$2K
- AbbVie$567
- Momentis Surgical Inc.$431
- Therapeuticsmd, Inc.$223
- plus $914 from 17 others
What the payments were for
- Consulting fees$6,02523%
- Travel & lodging$1,1925%
- Food & beverage$3,22412%
- Education$16,00061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $17,206 |
| Tesaro, Inc. | 13 | $4,875 |
| GSK | 3 | $2,225 |
| AbbVie | 23 | $567 |
| Momentis Surgical Inc. | 3 | $431 |
| Therapeuticsmd, Inc. | 6 | $223 |
| Myriad Genetic Laboratories, Inc. | 5 | $190 |
| BD | 2 | $150 |
| Merck | 5 | $146 |
| Mayne Pharma Commercial LLC | 3 | $85 |
| Aspira Women's Health Inc | 1 | $63 |
| AstraZeneca | 2 | $48 |
| Stryker | 1 | $29 |
| Genmab U.S., Inc. | 1 | $24 |
| Tempus AI, Inc | 1 | $24 |
| Verastem, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Meditrina | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Avion Pharmaceuticals | 1 | $19 |
| Evofem Biosciences, Inc. | 1 | $18 |
| Clovis Oncology, Inc. | 1 | $17 |
| Millicent US Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$17,200
- ZEJULA$4,575
- JEMPERLI$2,175
- Anovo Surgical System$381
- BIJUVA$120
- ARISTA$119
- myChoice CDx$101
How this compares
$26,441 in reported general payments places this provider in the 90th percentile of 25 gynecologic oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 33 | $2,361 |
| Clobetasol Propionate | 17 | $647 |
| Triamcinolone Acetonide | 12 | $32 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Stamford
- Gulden MenderesBridgeport$35K
- Gloria HuangNew Haven$27K
- Amy BrownHartford$23K
- Mitchell ClarkNew Haven$9K
- Xun ZhouNew Britain$5K
- Linus ChuangDanbury$3K
- Blair McNamaraNew Haven$1K
- Conway XuHartford$1K
- Aparna KailasamNew Haven$1K
- Erin HartnettHartford$869
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.